Adapalene-benzoyl peroxide, a fixed-dose combination for the treatment of acne vulgaris: Results of a multicenter, randomized double-blind, controlled study

A fixed-dose combination gel with adapalene 0.1% and benzoyl peroxide (BPO) 2.5% has been developed for the once-daily treatment of acne. To evaluate the efficacy and safety of adapalene 0.1% -BPO 2.5% fixed combination gel (adapalene-BPO) for the treatment of acne. A total of 517 subjects were rand...

Full description

Saved in:

Bibliographic Details
Published in	Journal of the American Academy of Dermatology Vol. 57; no. 5; pp. 791 - 799
Main Authors	Thiboutot, Diane M., Weiss, Jonathan, Bucko, Alicia, Eichenfield, Lawrence, Jones, Terry, Clark, Scott, Liu, Yin, Graeber, Michael, Kang, Sewon
Format	Journal Article
Language	English
Published	New York, NY Mosby, Inc 01.11.2007 Elsevier
Subjects	Acne Vulgaris - drug therapy Adapalene Adolescent Adult Benzoyl Peroxide - adverse effects Benzoyl Peroxide - therapeutic use Biological and medical sciences Child Dermatologic Agents - adverse effects Dermatologic Agents - therapeutic use Dermatology Double-Blind Method Drug Combinations Female Humans Male Medical sciences Middle Aged Naphthalenes - adverse effects Naphthalenes - therapeutic use Skin involvement in other diseases. Miscellaneous. General aspects Treatment Outcome BPO PP ITT IGA LOCF investigator's global assessment last observation carried forward per-protocol benzoyl peroxide intention-to-treat Acne vulgaris Skin disease Treatment Adapalene Dermatology Retinoid Double blind study Antiacneic agent Benzoyl peroxide Dose
Online Access	Get full text
ISSN	0190-9622 1097-6787 1097-6787
DOI	10.1016/j.jaad.2007.06.006

Cover

Abstract	A fixed-dose combination gel with adapalene 0.1% and benzoyl peroxide (BPO) 2.5% has been developed for the once-daily treatment of acne. To evaluate the efficacy and safety of adapalene 0.1% -BPO 2.5% fixed combination gel (adapalene-BPO) for the treatment of acne. A total of 517 subjects were randomized in a double-blind controlled trial to receive either adapalene-BPO, adapalene, BPO, or vehicle for 12 weeks (2:2:2:1 randomization). Evaluation included success rate (subjects “clear” or “almost clear”), lesion count, cutaneous tolerability, and adverse events. The fixed-dose combination gel of adapalene and BPO was significantly more effective than corresponding monotherapies, with significant differences in total lesion counts observed as early as 1 week. Adverse event frequency and cutaneous tolerability profile for adapalene-BPO were similar to adapalene monotherapy. These data were generated in a controlled trial. Results obtained in clinical practice could differ. The fixed-dose combination of adapalene and BPO provides significantly greater efficacy for the treatment of acne vulgaris as early as week 1 relative to monotherapies, with a comparable safety profile to adapalene.
AbstractList	Background A fixed-dose combination gel with adapalene 0.1% and benzoyl peroxide (BPO) 2.5% has been developed for the once-daily treatment of acne. Objective To evaluate the efficacy and safety of adapalene 0.1% -BPO 2.5% fixed combination gel (adapalene-BPO) for the treatment of acne. Methods A total of 517 subjects were randomized in a double-blind controlled trial to receive either adapalene-BPO, adapalene, BPO, or vehicle for 12 weeks (2:2:2:1 randomization). Evaluation included success rate (subjects “clear” or “almost clear”), lesion count, cutaneous tolerability, and adverse events. Results The fixed-dose combination gel of adapalene and BPO was significantly more effective than corresponding monotherapies, with significant differences in total lesion counts observed as early as 1 week. Adverse event frequency and cutaneous tolerability profile for adapalene-BPO were similar to adapalene monotherapy. Limitations These data were generated in a controlled trial. Results obtained in clinical practice could differ. Conclusions The fixed-dose combination of adapalene and BPO provides significantly greater efficacy for the treatment of acne vulgaris as early as week 1 relative to monotherapies, with a comparable safety profile to adapalene. A fixed-dose combination gel with adapalene 0.1% and benzoyl peroxide (BPO) 2.5% has been developed for the once-daily treatment of acne. To evaluate the efficacy and safety of adapalene 0.1% -BPO 2.5% fixed combination gel (adapalene-BPO) for the treatment of acne. A total of 517 subjects were randomized in a double-blind controlled trial to receive either adapalene-BPO, adapalene, BPO, or vehicle for 12 weeks (2:2:2:1 randomization). Evaluation included success rate (subjects "clear" or "almost clear"), lesion count, cutaneous tolerability, and adverse events. The fixed-dose combination gel of adapalene and BPO was significantly more effective than corresponding monotherapies, with significant differences in total lesion counts observed as early as 1 week. Adverse event frequency and cutaneous tolerability profile for adapalene-BPO were similar to adapalene monotherapy. These data were generated in a controlled trial. Results obtained in clinical practice could differ. The fixed-dose combination of adapalene and BPO provides significantly greater efficacy for the treatment of acne vulgaris as early as week 1 relative to monotherapies, with a comparable safety profile to adapalene. A fixed-dose combination gel with adapalene 0.1% and benzoyl peroxide (BPO) 2.5% has been developed for the once-daily treatment of acne.BACKGROUNDA fixed-dose combination gel with adapalene 0.1% and benzoyl peroxide (BPO) 2.5% has been developed for the once-daily treatment of acne.To evaluate the efficacy and safety of adapalene 0.1% -BPO 2.5% fixed combination gel (adapalene-BPO) for the treatment of acne.OBJECTIVETo evaluate the efficacy and safety of adapalene 0.1% -BPO 2.5% fixed combination gel (adapalene-BPO) for the treatment of acne.A total of 517 subjects were randomized in a double-blind controlled trial to receive either adapalene-BPO, adapalene, BPO, or vehicle for 12 weeks (2:2:2:1 randomization). Evaluation included success rate (subjects "clear" or "almost clear"), lesion count, cutaneous tolerability, and adverse events.METHODSA total of 517 subjects were randomized in a double-blind controlled trial to receive either adapalene-BPO, adapalene, BPO, or vehicle for 12 weeks (2:2:2:1 randomization). Evaluation included success rate (subjects "clear" or "almost clear"), lesion count, cutaneous tolerability, and adverse events.The fixed-dose combination gel of adapalene and BPO was significantly more effective than corresponding monotherapies, with significant differences in total lesion counts observed as early as 1 week. Adverse event frequency and cutaneous tolerability profile for adapalene-BPO were similar to adapalene monotherapy.RESULTSThe fixed-dose combination gel of adapalene and BPO was significantly more effective than corresponding monotherapies, with significant differences in total lesion counts observed as early as 1 week. Adverse event frequency and cutaneous tolerability profile for adapalene-BPO were similar to adapalene monotherapy.These data were generated in a controlled trial. Results obtained in clinical practice could differ.LIMITATIONSThese data were generated in a controlled trial. Results obtained in clinical practice could differ.The fixed-dose combination of adapalene and BPO provides significantly greater efficacy for the treatment of acne vulgaris as early as week 1 relative to monotherapies, with a comparable safety profile to adapalene.CONCLUSIONSThe fixed-dose combination of adapalene and BPO provides significantly greater efficacy for the treatment of acne vulgaris as early as week 1 relative to monotherapies, with a comparable safety profile to adapalene.
Author	Kang, Sewon Bucko, Alicia Jones, Terry Clark, Scott Liu, Yin Thiboutot, Diane M. Weiss, Jonathan Eichenfield, Lawrence Graeber, Michael
Author_xml	– sequence: 1 givenname: Diane M. surname: Thiboutot fullname: Thiboutot, Diane M. email: dthiboutot@psu.edu organization: The Pennsylvania State University College of Medicine, Milton S. Hershey Medical Center, Hershey, Pennsylvania – sequence: 2 givenname: Jonathan surname: Weiss fullname: Weiss, Jonathan organization: Gwinett Dermatology, P.C., Snellville, Georgia – sequence: 3 givenname: Alicia surname: Bucko fullname: Bucko, Alicia organization: Academic Dermatology Associates, Albuquerque, New Mexico – sequence: 4 givenname: Lawrence surname: Eichenfield fullname: Eichenfield, Lawrence organization: Children's Hospital San Diego, San Diego, California – sequence: 5 givenname: Terry surname: Jones fullname: Jones, Terry organization: J and S Studies, Inc, Bryan, Texas – sequence: 6 givenname: Scott surname: Clark fullname: Clark, Scott organization: Longmont Clinic PC, Longmont, Colorado – sequence: 7 givenname: Yin surname: Liu fullname: Liu, Yin organization: Galderma Research & Development, Princeton, New Jersey – sequence: 8 givenname: Michael surname: Graeber fullname: Graeber, Michael email: michael.graeber@galderma.com organization: Galderma Research & Development, Princeton, New Jersey – sequence: 9 givenname: Sewon surname: Kang fullname: Kang, Sewon organization: University of Michigan, Ann Arbor, Michigan
BackLink	http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19174389$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/17655969$$D View this record in MEDLINE/PubMed
BookMark	eNqFktuKFDEQhhtZcQ_6Al5IbvRqeqz0pA9ZRFgWT7AgeLgO6aRaM6aT2SS97Oyz-LCmd0aFBderBOr7q_jrr-PiwHmHRfGUwpICbV6ul2sp9bICaJfQLAGaB8URBd6WTdu1B8URUA4lb6rqsDiOcQ0AnK3aR8UhbZu65g0_Kn6eabmRFh2WPbobv7Vkg8FfG40LIslgrlGX2kckyo-9cTIZ78jgA0nfkaSAMo3oEvEDkcohuZrsNxlMPCWfME42xdsKGfPXqAxiWJAgnfajuUFNtJ96m0db4_Qij3ApeGtzIaZJbx8XDwdpIz7ZvyfF17dvvpy_Ly8-vvtwfnZRKsYhlZzXvGVSSUA66EEpYK2GnsqaMd72eqi7QUqmOqZZ16mhw15XtF2pnimsJV-dFC92fTfBX04YkxhNVGitdOinKJqOAayaGXy2B6d-RC02wYwybMXvfWbg-R6QUUk7ZKvKxL8cpy1bdTPX7TgVfIwBB6FMut1tCtJYQUHMEYu1mCMWc8QCGpEjztLqjvRP9_tEr3YizGu8MhhEVAadQm0CqiS0N_fLX9-Rq5yYyQ5_4Bbj2k_B5YAEFbESID7PhzffHbRAoWKz39N_N_jf9F92TutD
CODEN	JAADDB
CitedBy_id	crossref_primary_10_1586_edm_10_57 crossref_primary_10_1016_S1634_7358_10_70325_9 crossref_primary_10_1111_j_1365_2133_2009_09209_x crossref_primary_10_25208_0042_4609_2016_92_2_81_86 crossref_primary_10_1007_s00403_015_1568_9 crossref_primary_10_1111_bjd_12186 crossref_primary_10_2147_CCID_S400226 crossref_primary_10_1002_14651858_CD011154_pub2 crossref_primary_10_1097_JD9_0000000000000279 crossref_primary_10_1111_j_1600_0625_2011_01339_x crossref_primary_10_1111_j_1365_2230_2011_04214_x crossref_primary_10_3109_09546634_2013_851924 crossref_primary_10_1586_edm_11_3 crossref_primary_10_18410_jebmh_2017_1071 crossref_primary_10_25208_vdv701 crossref_primary_10_1089_photob_2024_0074 crossref_primary_10_1155_2014_276260 crossref_primary_10_1111_jocd_12013 crossref_primary_10_1111_jocd_12497 crossref_primary_10_4103_jrms_JRMS_398_19 crossref_primary_10_1016_S1636_5410_10_70507_9 crossref_primary_10_3109_09546634_2015_1079298 crossref_primary_10_1517_14656566_9_6_955 crossref_primary_10_3109_09546634_2016_1145338 crossref_primary_10_12968_joan_2014_3_1_20 crossref_primary_10_1007_s13555_014_0054_1 crossref_primary_10_3109_09546634_2012_751085 crossref_primary_10_1021_jo300297u crossref_primary_10_1111_jdv_13194 crossref_primary_10_3109_09546631003681094 crossref_primary_10_1016_j_jpp_2010_11_005 crossref_primary_10_1586_edm_10_32 crossref_primary_10_1111_ajd_12465 crossref_primary_10_1111_j_1468_3083_2011_04374_x crossref_primary_10_17116_klinderma202221041442 crossref_primary_10_1007_s40257_021_00650_3 crossref_primary_10_1517_14656560903277228 crossref_primary_10_1111_j_1610_0387_2008_06741_x crossref_primary_10_1021_cr100264t crossref_primary_10_3810_pgm_2011_05_2294 crossref_primary_10_1111_bjd_20080 crossref_primary_10_1517_17425250903386269 crossref_primary_10_1111_j_1468_3083_2010_03685_x crossref_primary_10_1111_j_1468_2494_2011_00647_x crossref_primary_10_3390_jcm11247535 crossref_primary_10_1111_jdv_20154 crossref_primary_10_1016_S1245_1789_11_71003_4 crossref_primary_10_1080_09546630802132635 crossref_primary_10_1111_1346_8138_12979 crossref_primary_10_1111_1346_8138_14355 crossref_primary_10_1007_s00105_008_1498_y crossref_primary_10_7759_cureus_69341 crossref_primary_10_1080_14656566_2024_2418986 crossref_primary_10_2165_0128071_200809060_00003 crossref_primary_10_1016_j_ijpharm_2020_119074 crossref_primary_10_1016_j_jaad_2007_11_003 crossref_primary_10_1016_S1634_6939_10_51459_5 crossref_primary_10_1111_jdv_17140 crossref_primary_10_1111_1346_8138_13996 crossref_primary_10_1016_j_jaad_2009_01_019 crossref_primary_10_1038_jid_2012_292 crossref_primary_10_1080_14656566_2021_1990263 crossref_primary_10_1111_jocd_15178 crossref_primary_10_3390_ph13090217 crossref_primary_10_2165_11597880_000000000_00000 crossref_primary_10_5021_ad_2014_26_1_43 crossref_primary_10_2165_11208170_000000000_00000 crossref_primary_10_33590_emjdermatol_10313031 crossref_primary_10_1111_jdv_14026 crossref_primary_10_1586_17469872_4_1_55 crossref_primary_10_1016_j_ejps_2017_10_033 crossref_primary_10_4103_ijdd_ijdd_29_20 crossref_primary_10_36290_der_2021_003 crossref_primary_10_1590_abd1806_4841_20153969 crossref_primary_10_1155_2022_3644720 crossref_primary_10_1111_ddg_12613_suppl crossref_primary_10_1016_S1637_5017_10_72476_5 crossref_primary_10_1007_s13555_016_0159_9 crossref_primary_10_1111_j_1365_2133_2011_10344_x crossref_primary_10_1186_s13063_020_04432_w crossref_primary_10_3390_app122413039 crossref_primary_10_2165_11532280_000000000_00000 crossref_primary_10_1111_1346_8138_13191 crossref_primary_10_1016_j_clindermatol_2016_10_010 crossref_primary_10_1080_14656566_2017_1282460 crossref_primary_10_1111_j_1365_2133_2009_09531_x crossref_primary_10_1111_bjd_13191 crossref_primary_10_1097_01_AOG_0000358101_72439_05 crossref_primary_10_1111_ddg_12613 crossref_primary_10_1111_jdv_12989 crossref_primary_10_1586_ecp_10_27 crossref_primary_10_1111_j_1365_2133_2011_10374_x crossref_primary_10_1016_j_jaad_2022_08_069 crossref_primary_10_1016_j_jaad_2010_03_036 crossref_primary_10_1080_09546634_2023_2220446 crossref_primary_10_1097_MOP_0b013e3283425457 crossref_primary_10_2310_7750_2013_13154 crossref_primary_10_18410_jebmh_2019_484 crossref_primary_10_2165_00128071_200910030_00009 crossref_primary_10_1586_edm_09_21 crossref_primary_10_1007_s13555_017_0203_4
Cites_doi	10.1111/j.1540-9740.2005.04279.x 10.2165/00003495-200464130-00005 10.1016/S0190-9622(97)70050-1 10.1067/S0190-9622(03)01154-X 10.1016/S0190-9622(97)70052-5 10.1067/S0190-9622(03)01153-8 10.1046/j.1365-2133.1998.1390s2017.x 10.1159/000017844 10.1067/S0190-9622(03)01151-4 10.2165/00003495-199753030-00010 10.1111/j.1365-4362.1986.tb04534.x 10.1067/S0190-9622(03)01152-6 10.1001/jama.292.6.726 10.1016/S0190-9622(97)70053-7 10.1046/j.1365-2133.1998.1390s2048.x 10.1046/j.1365-2133.1998.1390s2003.x 10.1001/archfami.9.2.179 10.1053/sder.2001.28207 10.1067/mjd.2003.618 10.1016/S0190-9622(97)70177-4 10.1046/j.1365-2133.1998.1390s2008.x 10.1080/09546630410021702 10.1097/01.JDN.0000350427.23616.3b
ContentType	Journal Article
Copyright	2007 American Academy of Dermatology, Inc. American Academy of Dermatology, Inc. 2007 INIST-CNRS
Copyright_xml	– notice: 2007 American Academy of Dermatology, Inc. – notice: American Academy of Dermatology, Inc. – notice: 2007 INIST-CNRS
CorporateAuthor	Adapalene-BPO Study Group
CorporateAuthor_xml	– name: Adapalene-BPO Study Group
DBID	AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1016/j.jaad.2007.06.006
DatabaseName	CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1097-6787
EndPage	799
ExternalDocumentID	17655969 19174389 10_1016_j_jaad_2007_06_006 S0190962207010249 1_s2_0_S0190962207010249
Genre	Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article
GroupedDBID	--- --K --M -RU .1- .FO .GJ .XZ .~1 0R~ 1B1 1CY 1P~ 1RT 1~. 1~5 354 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 6PF 7-5 71M 8F7 8P~ 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AAQXK AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABJNI ABMAC ABMZM ABWVN ABXDB ACDAQ ACGFO ACGFS ACIEU ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO ADVLN AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFFNX AFJKZ AFPUW AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AGUBO AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV C45 CAG COF CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HEA HMK HMO HVGLF HX~ HZ~ IHE J1W J5H KOM LZ2 M27 M41 MO0 N9A O-L O9- OAUVE OB. OBH OHH OM~ OVD OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SAE SDF SDG SDP SEL SES SJN SPCBC SSH SSZ T5K TEORI UHS UNMZH UV1 WOW WUQ Y6R YFH Z5R ZCG ZGI ZY1 ~G- AACTN AFCTW AFKWA AJOXV AMFUW PKN RIG AAIAV ABLVK ABYKQ AJBFU EFLBG LCYCR AAYXX AGRNS CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 ACLOT ~HD
ID	FETCH-LOGICAL-c490t-995974aca0e1fdfcc047d0b1a54497bdf58faa4c84d488cf8ebd2173cb4ce5a93
IEDL.DBID	.~1
ISSN	0190-9622 1097-6787
IngestDate	Sun Sep 28 00:59:59 EDT 2025 Thu Apr 03 07:00:20 EDT 2025 Mon Jul 21 09:13:14 EDT 2025 Thu Apr 24 23:04:41 EDT 2025 Tue Jul 01 01:26:25 EDT 2025 Fri Feb 23 02:32:57 EST 2024 Sun Feb 23 10:19:04 EST 2025 Tue Aug 26 19:52:31 EDT 2025
IsPeerReviewed	true
IsScholarly	true
Issue	5
Keywords	BPO PP ITT IGA LOCF investigator's global assessment last observation carried forward per-protocol benzoyl peroxide intention-to-treat Acne vulgaris Skin disease Treatment Adapalene Dermatology Retinoid Double blind study Antiacneic agent Benzoyl peroxide Dose
Language	English
License	https://www.elsevier.com/tdm/userlicense/1.0 CC BY 4.0
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c490t-995974aca0e1fdfcc047d0b1a54497bdf58faa4c84d488cf8ebd2173cb4ce5a93
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3
PMID	17655969
PQID	68400369
PQPubID	23479
PageCount	9
ParticipantIDs	proquest_miscellaneous_68400369 pubmed_primary_17655969 pascalfrancis_primary_19174389 crossref_citationtrail_10_1016_j_jaad_2007_06_006 crossref_primary_10_1016_j_jaad_2007_06_006 elsevier_sciencedirect_doi_10_1016_j_jaad_2007_06_006 elsevier_clinicalkeyesjournals_1_s2_0_S0190962207010249 elsevier_clinicalkey_doi_10_1016_j_jaad_2007_06_006
ProviderPackageCode	CITATION AAYXX
PublicationCentury	2000
PublicationDate	2007-11-01
PublicationDateYYYYMMDD	2007-11-01
PublicationDate_xml	– month: 11 year: 2007 text: 2007-11-01 day: 01
PublicationDecade	2000
PublicationPlace	New York, NY
PublicationPlace_xml	– name: New York, NY – name: United States
PublicationTitle	Journal of the American Academy of Dermatology
PublicationTitleAlternate	J Am Acad Dermatol
PublicationYear	2007
Publisher	Mosby, Inc Elsevier
Publisher_xml	– name: Mosby, Inc – name: Elsevier
References	Michel, Jomard, Demarchez (bib6) 1998; 139 Dunlap, Mills, Tuley, Baker, Plott (bib15) 1998; 139 Egan, Loesche, Baker (bib17) 2001; 68 Martin, Meunier, Montels, Watts (bib29) 1998; 139 Leyden (bib2) 2003; 49 Caron, Sorba, Clucas, Verschoore (bib19) 1997; 36 Greenspan, Loesche, Vendetti, Georgeian, Gilbert, Poncet (bib14) 2003; 72 Zhang, Li, Tu, Zheng (bib22) 2004; 15 Plewig, Kligman (bib24) 2000 Dosik, Homer, Arsonnaud (bib13) 2005; 75 Haider, Shaw (bib9) 2004; 292 Brand, Gilbert, Baker, Poncet, Greenspan, Georgeian (bib18) 2003; 49 (bib34) 2005; 6 Thiboutot, Shalita, Yamauchi, Dawson, Arsonnaud, Kang (bib23) 2005; 4 Brogden, Goa (bib5) 1997; 53 Mills, Kligman, Pochi, Comite (bib30) 1986; 25 Waugh, Noble, Scott (bib11) 2004; 64 Leyden (bib25) 2001; 20 Caron, Sorba, Kerrouche, Clucas (bib16) 1997; 36 Bowman, Gold, Nasir, Vamvakias (bib26) 2005; 4 Gollnick, Cunliffe, Berson, Dreno, Finlay, Leyden (bib3) 2003; 49 Cunliffe, Meynadier, Alirezai, George, Coutts, Roseeuw (bib21) 2003; 49 Data on file. Galderma Laboratories. Cunliffe, Poncet, Loesche, Verschoore (bib10) 1998; 139 Bikowski (bib27) 2005; 4 Thiboutot (bib32) 2000; 9 Lavker, Leyden, Thorne (bib33) 1992; 14 Lookingbill, Chalker, Lindholm, Katz, Kempers, Huerter (bib28) 1997; 37 Vega, Jomard, Michel (bib7) 2002; 16 Wolf, Kaplan, Kraus, Loven, Rist, Swinyer (bib20) 2003; 49 Pawin, Beylot, Chivot, Faure, Poli, Revuz (bib1) 2004; 14 Gollnick, Schramm (bib4) 1998; 196 Pariser DM, Westmoreland P, Morris A, Gold MH, Liu Y, Graeber M. Long-term safety and efficacy of a unique fixed-dose combination gel of adapalene 0.1% and benzoyl peroxide 2.5% for the treatment of acne vulgaris. Drugs in Dermatol. In press. Shroot, Michel (bib8) 1997; 36 Dosik, Homer, Arsonnaud (bib12) 2005; 75 Brogden (10.1016/j.jaad.2007.06.006_bib5) 1997; 53 Michel (10.1016/j.jaad.2007.06.006_bib6) 1998; 139 Leyden (10.1016/j.jaad.2007.06.006_bib25) 2001; 20 Shroot (10.1016/j.jaad.2007.06.006_bib8) 1997; 36 Cunliffe (10.1016/j.jaad.2007.06.006_bib10) 1998; 139 Dosik (10.1016/j.jaad.2007.06.006_bib12) 2005; 75 10.1016/j.jaad.2007.06.006_bib35 Zhang (10.1016/j.jaad.2007.06.006_bib22) 2004; 15 Caron (10.1016/j.jaad.2007.06.006_bib16) 1997; 36 Martin (10.1016/j.jaad.2007.06.006_bib29) 1998; 139 Thiboutot (10.1016/j.jaad.2007.06.006_bib23) 2005; 4 Lookingbill (10.1016/j.jaad.2007.06.006_bib28) 1997; 37 Lavker (10.1016/j.jaad.2007.06.006_bib33) 1992; 14 Pawin (10.1016/j.jaad.2007.06.006_bib1) 2004; 14 Haider (10.1016/j.jaad.2007.06.006_bib9) 2004; 292 Dunlap (10.1016/j.jaad.2007.06.006_bib15) 1998; 139 Waugh (10.1016/j.jaad.2007.06.006_bib11) 2004; 64 Greenspan (10.1016/j.jaad.2007.06.006_bib14) 2003; 72 Vega (10.1016/j.jaad.2007.06.006_bib7) 2002; 16 Wolf (10.1016/j.jaad.2007.06.006_bib20) 2003; 49 Plewig (10.1016/j.jaad.2007.06.006_bib24) 2000 Brand (10.1016/j.jaad.2007.06.006_bib18) 2003; 49 Bikowski (10.1016/j.jaad.2007.06.006_bib27) 2005; 4 (10.1016/j.jaad.2007.06.006_bib34) 2005; 6 Gollnick (10.1016/j.jaad.2007.06.006_bib3) 2003; 49 Leyden (10.1016/j.jaad.2007.06.006_bib2) 2003; 49 Cunliffe (10.1016/j.jaad.2007.06.006_bib21) 2003; 49 Egan (10.1016/j.jaad.2007.06.006_bib17) 2001; 68 Thiboutot (10.1016/j.jaad.2007.06.006_bib32) 2000; 9 Caron (10.1016/j.jaad.2007.06.006_bib19) 1997; 36 10.1016/j.jaad.2007.06.006_bib31 Bowman (10.1016/j.jaad.2007.06.006_bib26) 2005; 4 Mills (10.1016/j.jaad.2007.06.006_bib30) 1986; 25 Gollnick (10.1016/j.jaad.2007.06.006_bib4) 1998; 196 Dosik (10.1016/j.jaad.2007.06.006_bib13) 2005; 75
References_xml	– reference: Pariser DM, Westmoreland P, Morris A, Gold MH, Liu Y, Graeber M. Long-term safety and efficacy of a unique fixed-dose combination gel of adapalene 0.1% and benzoyl peroxide 2.5% for the treatment of acne vulgaris. Drugs in Dermatol. In press. – volume: 16 start-page: 123 year: 2002 end-page: 124 ident: bib7 article-title: Regulation of human monocyte toll-like receptor 2 (TLR2) expression by adapalene publication-title: J Eur Acad Dermatol Venereol – volume: 49 start-page: S1 year: 2003 end-page: S37 ident: bib3 article-title: Management of acne. A report from a Global Alliance to Improve Outcomes in Acne publication-title: J Am Acad Dermatol – volume: 53 start-page: 511 year: 1997 end-page: 519 ident: bib5 article-title: Adapalene: a review of its pharmacological properties and clinical potential in the management of mild to moderate acne publication-title: Drugs – volume: 37 start-page: 590 year: 1997 end-page: 595 ident: bib28 article-title: Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double-blind investigations publication-title: J Am Acad Dermatol – volume: 20 start-page: 139 year: 2001 end-page: 143 ident: bib25 article-title: The evolving role of P acnes in acne publication-title: Semin Cutan Med Surg – volume: 292 start-page: 726 year: 2004 end-page: 735 ident: bib9 article-title: Treatment of acne vulgaris publication-title: JAMA – volume: 75 start-page: 289 year: 2005 end-page: 293 ident: bib12 article-title: Cumulative irritation potential of adapalene 0.1% cream and gel compared with tazarotene cream 0.05% and 0.1% publication-title: Cutis – volume: 139 start-page: 17 year: 1998 end-page: 22 ident: bib15 article-title: Adapalene 0.1% gel for the treatment of acne vulgaris: its superiority compared to tretinoin 0.025% cream in skin tolerance and patient preference publication-title: Br J Dermatol – volume: 36 start-page: S96 year: 1997 end-page: S103 ident: bib8 article-title: Pharmacology and chemistry of adapalene publication-title: J Am Acad Dermatol – volume: 15 start-page: 372 year: 2004 end-page: 378 ident: bib22 article-title: A successful maintenance approach in inflammatory acne with adapalene gel 0.1% after an initial treatment in combination with clindamycin topical solution 1% or after monotherapy with clindamycin topical solution 1% publication-title: J Dermatolog Treat – volume: 49 start-page: S211 year: 2003 end-page: S217 ident: bib20 article-title: Efficacy and tolerability of combined topical treatment of acne vulgaris with adapalene and clindamycin: a multicenter, randomized, investigator-blinded study publication-title: J Am Acad Dermatol – volume: 49 start-page: S218 year: 2003 end-page: S226 ident: bib21 article-title: Is combined oral and topical therapy better than oral therapy alone in patients with moderate to moderately severe acne vulgaris? A comparison of the efficacy and safety of lymecycline plus adapalene gel 0.1%, versus lymecycline plus gel vehicle publication-title: J Am Acad Dermatol – volume: 14 start-page: 773 year: 1992 end-page: 780 ident: bib33 article-title: An ultrastructural study of the effects of topical tretinoin on microcomedones publication-title: Clin Ther – volume: 36 start-page: S113 year: 1997 end-page: S115 ident: bib19 article-title: Skin tolerance of adapalene 0.1% gel in combination with other topical antiacne treatments publication-title: J Am Acad Dermatol – volume: 9 start-page: 179 year: 2000 end-page: 187 ident: bib32 article-title: New treatments and therapeutic strategies for acne publication-title: Arch Family Med – volume: 14 start-page: 4 year: 2004 end-page: 12 ident: bib1 article-title: Physiopathology of acne vulgaris: recent data, new understanding of the treatments publication-title: Eur J Dermatol – volume: 4 start-page: 611 year: 2005 end-page: 618 ident: bib26 article-title: Comparison of clindamycin/benzoyl peroxide, tretinoin plus clindamycin, and the combination of clindamycin/benzoyl peroxide and tretinoin plus clindamycin in the treatment of acne vulgaris: a randomized, blinded study publication-title: J Drugs Dermatol – volume: 196 start-page: 119 year: 1998 end-page: 125 ident: bib4 article-title: Topical drug treatment in acne publication-title: Dermatology – volume: 64 start-page: 1465 year: 2004 end-page: 1478 ident: bib11 article-title: Adapalene: a review of its use in the treatment of acne vulgaris publication-title: Drugs – year: 2000 ident: bib24 article-title: Acne and rosacea – volume: 49 start-page: S200 year: 2003 end-page: S210 ident: bib2 article-title: A review of the use of combination therapies for the treatment of acne vulgaris publication-title: J Am Acad Dermatol – volume: 6 start-page: 231 year: 2005 end-page: 234 ident: bib34 article-title: Clindamycin/tretinoin publication-title: Drugs – volume: 139 start-page: 3 year: 1998 end-page: 7 ident: bib6 article-title: Pharmacology of adapalene publication-title: Br J Dermatol – volume: 75 start-page: 238 year: 2005 end-page: 243 ident: bib13 article-title: Cumulative irritation potential of adapalene 0.1% cream and gel compared to tretinoin micro sphere 0.04% and 0.1% publication-title: Cutis – volume: 4 start-page: 138 year: 2005 end-page: 146 ident: bib23 article-title: Combination therapy with adapalene gel 0.1% and doxycycline for severe acne vulgaris: a multicenter, investigator-blind, randomized, controlled study publication-title: Skinmed – volume: 68 start-page: 20 year: 2001 end-page: 24 ident: bib17 article-title: Randomized, controlled, bilateral (split-face) comparison trial of the tolerability and patient preference of adapalene gel 0.1% and tretinoin microsphere gel 0.1% for the treatment of acne vulgaris publication-title: Cutis – volume: 25 start-page: 664 year: 1986 end-page: 667 ident: bib30 article-title: Comparing 2.5%, 5%, and 10% benzoyl peroxide on inflammatory acne vulgaris publication-title: Int J Dermatol – volume: 4 start-page: 164 year: 2005 end-page: 171 ident: bib27 article-title: Clinical experience results with clindamycin 1% benzoyl peroxide 5% gel as monotherapy and in combination publication-title: J Drugs Dermatol – volume: 139 start-page: 48 year: 1998 end-page: 56 ident: bib10 article-title: A comparison of the efficacy and tolerability of adapalene 0.1% gel versus tretinoin 0.025% gel in patients with acne vulgaris: a meta-analysis of five randomized trials publication-title: Br J Dermatol – volume: 36 start-page: S110 year: 1997 end-page: S112 ident: bib16 article-title: Split-face comparison of adapalene 0.1% gel and tretinoin 0.025% gel in acne patients publication-title: J Am Acad Dermatol – volume: 72 start-page: 76 year: 2003 end-page: 81 ident: bib14 article-title: Cumulative irritation comparison of adapalene gel and solution with 2 tazarotene gels and 3 tretinoin formulations publication-title: Cutis – reference: Data on file. Galderma Laboratories. – volume: 139 start-page: 8 year: 1998 end-page: 11 ident: bib29 article-title: Chemical stability of adapalene and tretinoin when combined with benzoyl peroxide in presence and in absence of visible light and ultraviolet radiation publication-title: Br J Dermatol – volume: 49 start-page: S227 year: 2003 end-page: S232 ident: bib18 article-title: Cumulative irritancy comparison of adapalene gel 0.1% versus other retinoid products when applied in combination with topical antimicrobial agents publication-title: J Am Acad Dermatol – volume: 4 start-page: 138 issue: 3 year: 2005 ident: 10.1016/j.jaad.2007.06.006_bib23 article-title: Combination therapy with adapalene gel 0.1% and doxycycline for severe acne vulgaris: a multicenter, investigator-blind, randomized, controlled study publication-title: Skinmed doi: 10.1111/j.1540-9740.2005.04279.x – volume: 64 start-page: 1465 year: 2004 ident: 10.1016/j.jaad.2007.06.006_bib11 article-title: Adapalene: a review of its use in the treatment of acne vulgaris publication-title: Drugs doi: 10.2165/00003495-200464130-00005 – volume: 36 start-page: S96 issue: Suppl year: 1997 ident: 10.1016/j.jaad.2007.06.006_bib8 article-title: Pharmacology and chemistry of adapalene publication-title: J Am Acad Dermatol doi: 10.1016/S0190-9622(97)70050-1 – volume: 16 start-page: 123 issue: 1 Suppl year: 2002 ident: 10.1016/j.jaad.2007.06.006_bib7 article-title: Regulation of human monocyte toll-like receptor 2 (TLR2) expression by adapalene publication-title: J Eur Acad Dermatol Venereol – volume: 68 start-page: 20 issue: 4 Suppl year: 2001 ident: 10.1016/j.jaad.2007.06.006_bib17 article-title: Randomized, controlled, bilateral (split-face) comparison trial of the tolerability and patient preference of adapalene gel 0.1% and tretinoin microsphere gel 0.1% for the treatment of acne vulgaris publication-title: Cutis – volume: 49 start-page: S200 issue: Suppl year: 2003 ident: 10.1016/j.jaad.2007.06.006_bib2 article-title: A review of the use of combination therapies for the treatment of acne vulgaris publication-title: J Am Acad Dermatol doi: 10.1067/S0190-9622(03)01154-X – volume: 36 start-page: S110 issue: Suppl year: 1997 ident: 10.1016/j.jaad.2007.06.006_bib16 article-title: Split-face comparison of adapalene 0.1% gel and tretinoin 0.025% gel in acne patients publication-title: J Am Acad Dermatol doi: 10.1016/S0190-9622(97)70052-5 – volume: 49 start-page: S218 issue: 3 Suppl year: 2003 ident: 10.1016/j.jaad.2007.06.006_bib21 article-title: Is combined oral and topical therapy better than oral therapy alone in patients with moderate to moderately severe acne vulgaris? A comparison of the efficacy and safety of lymecycline plus adapalene gel 0.1%, versus lymecycline plus gel vehicle publication-title: J Am Acad Dermatol doi: 10.1067/S0190-9622(03)01153-8 – volume: 139 start-page: 17 year: 1998 ident: 10.1016/j.jaad.2007.06.006_bib15 article-title: Adapalene 0.1% gel for the treatment of acne vulgaris: its superiority compared to tretinoin 0.025% cream in skin tolerance and patient preference publication-title: Br J Dermatol doi: 10.1046/j.1365-2133.1998.1390s2017.x – volume: 196 start-page: 119 year: 1998 ident: 10.1016/j.jaad.2007.06.006_bib4 article-title: Topical drug treatment in acne publication-title: Dermatology doi: 10.1159/000017844 – volume: 75 start-page: 238 year: 2005 ident: 10.1016/j.jaad.2007.06.006_bib13 article-title: Cumulative irritation potential of adapalene 0.1% cream and gel compared to tretinoin micro sphere 0.04% and 0.1% publication-title: Cutis – volume: 49 start-page: S227 issue: 3 Suppl year: 2003 ident: 10.1016/j.jaad.2007.06.006_bib18 article-title: Cumulative irritancy comparison of adapalene gel 0.1% versus other retinoid products when applied in combination with topical antimicrobial agents publication-title: J Am Acad Dermatol doi: 10.1067/S0190-9622(03)01151-4 – volume: 53 start-page: 511 year: 1997 ident: 10.1016/j.jaad.2007.06.006_bib5 article-title: Adapalene: a review of its pharmacological properties and clinical potential in the management of mild to moderate acne publication-title: Drugs doi: 10.2165/00003495-199753030-00010 – volume: 25 start-page: 664 year: 1986 ident: 10.1016/j.jaad.2007.06.006_bib30 article-title: Comparing 2.5%, 5%, and 10% benzoyl peroxide on inflammatory acne vulgaris publication-title: Int J Dermatol doi: 10.1111/j.1365-4362.1986.tb04534.x – volume: 14 start-page: 4 year: 2004 ident: 10.1016/j.jaad.2007.06.006_bib1 article-title: Physiopathology of acne vulgaris: recent data, new understanding of the treatments publication-title: Eur J Dermatol – volume: 49 start-page: S211 issue: 3 Suppl year: 2003 ident: 10.1016/j.jaad.2007.06.006_bib20 article-title: Efficacy and tolerability of combined topical treatment of acne vulgaris with adapalene and clindamycin: a multicenter, randomized, investigator-blinded study publication-title: J Am Acad Dermatol doi: 10.1067/S0190-9622(03)01152-6 – volume: 4 start-page: 164 year: 2005 ident: 10.1016/j.jaad.2007.06.006_bib27 article-title: Clinical experience results with clindamycin 1% benzoyl peroxide 5% gel as monotherapy and in combination publication-title: J Drugs Dermatol – ident: 10.1016/j.jaad.2007.06.006_bib31 – year: 2000 ident: 10.1016/j.jaad.2007.06.006_bib24 – volume: 292 start-page: 726 year: 2004 ident: 10.1016/j.jaad.2007.06.006_bib9 article-title: Treatment of acne vulgaris publication-title: JAMA doi: 10.1001/jama.292.6.726 – volume: 36 start-page: S113 issue: Suppl year: 1997 ident: 10.1016/j.jaad.2007.06.006_bib19 article-title: Skin tolerance of adapalene 0.1% gel in combination with other topical antiacne treatments publication-title: J Am Acad Dermatol doi: 10.1016/S0190-9622(97)70053-7 – volume: 139 start-page: 48 year: 1998 ident: 10.1016/j.jaad.2007.06.006_bib10 article-title: A comparison of the efficacy and tolerability of adapalene 0.1% gel versus tretinoin 0.025% gel in patients with acne vulgaris: a meta-analysis of five randomized trials publication-title: Br J Dermatol doi: 10.1046/j.1365-2133.1998.1390s2048.x – volume: 14 start-page: 773 year: 1992 ident: 10.1016/j.jaad.2007.06.006_bib33 article-title: An ultrastructural study of the effects of topical tretinoin on microcomedones publication-title: Clin Ther – volume: 139 start-page: 3 issue: 52 Suppl year: 1998 ident: 10.1016/j.jaad.2007.06.006_bib6 article-title: Pharmacology of adapalene publication-title: Br J Dermatol doi: 10.1046/j.1365-2133.1998.1390s2003.x – volume: 75 start-page: 289 year: 2005 ident: 10.1016/j.jaad.2007.06.006_bib12 article-title: Cumulative irritation potential of adapalene 0.1% cream and gel compared with tazarotene cream 0.05% and 0.1% publication-title: Cutis – volume: 9 start-page: 179 year: 2000 ident: 10.1016/j.jaad.2007.06.006_bib32 article-title: New treatments and therapeutic strategies for acne publication-title: Arch Family Med doi: 10.1001/archfami.9.2.179 – volume: 20 start-page: 139 year: 2001 ident: 10.1016/j.jaad.2007.06.006_bib25 article-title: The evolving role of P acnes in acne publication-title: Semin Cutan Med Surg doi: 10.1053/sder.2001.28207 – volume: 49 start-page: S1 issue: 1 Suppl year: 2003 ident: 10.1016/j.jaad.2007.06.006_bib3 article-title: Management of acne. A report from a Global Alliance to Improve Outcomes in Acne publication-title: J Am Acad Dermatol doi: 10.1067/mjd.2003.618 – volume: 37 start-page: 590 year: 1997 ident: 10.1016/j.jaad.2007.06.006_bib28 article-title: Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double-blind investigations publication-title: J Am Acad Dermatol doi: 10.1016/S0190-9622(97)70177-4 – volume: 4 start-page: 611 year: 2005 ident: 10.1016/j.jaad.2007.06.006_bib26 article-title: Comparison of clindamycin/benzoyl peroxide, tretinoin plus clindamycin, and the combination of clindamycin/benzoyl peroxide and tretinoin plus clindamycin in the treatment of acne vulgaris: a randomized, blinded study publication-title: J Drugs Dermatol – volume: 139 start-page: 8 issue: 52 Suppl year: 1998 ident: 10.1016/j.jaad.2007.06.006_bib29 article-title: Chemical stability of adapalene and tretinoin when combined with benzoyl peroxide in presence and in absence of visible light and ultraviolet radiation publication-title: Br J Dermatol doi: 10.1046/j.1365-2133.1998.1390s2008.x – volume: 6 start-page: 231 year: 2005 ident: 10.1016/j.jaad.2007.06.006_bib34 article-title: Clindamycin/tretinoin publication-title: Drugs – volume: 72 start-page: 76 year: 2003 ident: 10.1016/j.jaad.2007.06.006_bib14 article-title: Cumulative irritation comparison of adapalene gel and solution with 2 tazarotene gels and 3 tretinoin formulations publication-title: Cutis – volume: 15 start-page: 372 year: 2004 ident: 10.1016/j.jaad.2007.06.006_bib22 article-title: A successful maintenance approach in inflammatory acne with adapalene gel 0.1% after an initial treatment in combination with clindamycin topical solution 1% or after monotherapy with clindamycin topical solution 1% publication-title: J Dermatolog Treat doi: 10.1080/09546630410021702 – ident: 10.1016/j.jaad.2007.06.006_bib35 doi: 10.1097/01.JDN.0000350427.23616.3b
SSID	ssj0009437
Score	2.3293548
Snippet	A fixed-dose combination gel with adapalene 0.1% and benzoyl peroxide (BPO) 2.5% has been developed for the once-daily treatment of acne. To evaluate the... Background A fixed-dose combination gel with adapalene 0.1% and benzoyl peroxide (BPO) 2.5% has been developed for the once-daily treatment of acne. Objective... A fixed-dose combination gel with adapalene 0.1% and benzoyl peroxide (BPO) 2.5% has been developed for the once-daily treatment of acne.BACKGROUNDA fixed-dose...
SourceID	proquest pubmed pascalfrancis crossref elsevier
SourceType	Aggregation Database Index Database Enrichment Source Publisher
StartPage	791
SubjectTerms	Acne Vulgaris - drug therapy Adapalene Adolescent Adult Benzoyl Peroxide - adverse effects Benzoyl Peroxide - therapeutic use Biological and medical sciences Child Dermatologic Agents - adverse effects Dermatologic Agents - therapeutic use Dermatology Double-Blind Method Drug Combinations Female Humans Male Medical sciences Middle Aged Naphthalenes - adverse effects Naphthalenes - therapeutic use Skin involvement in other diseases. Miscellaneous. General aspects Treatment Outcome
Title	Adapalene-benzoyl peroxide, a fixed-dose combination for the treatment of acne vulgaris: Results of a multicenter, randomized double-blind, controlled study
URI	https://www.clinicalkey.com/#!/content/1-s2.0-S0190962207010249 https://www.clinicalkey.es/playcontent/1-s2.0-S0190962207010249 https://dx.doi.org/10.1016/j.jaad.2007.06.006 https://www.ncbi.nlm.nih.gov/pubmed/17655969 https://www.proquest.com/docview/68400369
Volume	57
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVESC databaseName: Elsevier ScienceDirect Freedom Collection customDbUrl: eissn: 1097-6787 dateEnd: 20170228 omitProxy: true ssIdentifier: ssj0009437 issn: 0190-9622 databaseCode: AIKHN dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier SD Complete Freedom Collection [SCCMFC] customDbUrl: eissn: 1097-6787 dateEnd: 20170228 omitProxy: true ssIdentifier: ssj0009437 issn: 0190-9622 databaseCode: ACRLP dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection customDbUrl: eissn: 1097-6787 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0009437 issn: 0190-9622 databaseCode: .~1 dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVLSH databaseName: Elsevier Journals customDbUrl: mediaType: online eissn: 1097-6787 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0009437 issn: 0190-9622 databaseCode: AKRWK dateStart: 19790701 isFulltext: true providerName: Library Specific Holdings
link	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Jb9QwFLaqIiEkhNgZlsEHbkxoFmcxt1FFNTBqD4WK3iwvz1KqIRk1M6j0wC_hx_LsODOqoEXiFCnxS5z4-S3x9z0T8kZzxbXE-W0ssIjJREcyS2WEpyqVcUjB8ysOj4rZCft0mp_ukP2BC-NglcH29zbdW-twZi98zb1lXe99dixoXqQpKm3iCt85BjsrHKzv3c8tzIOzbEOZdq0DcabHeJ1JaUIZQ7cmUVznnO4uZYefzPZ7XVwfjHqndHCf3AvRJJ32HX5AdqB5SG4fhvXyR-TX1KAzRMcCkYLmsv2xoK4w-EVtYEIltfUFmMi0HVB8f8yR_TBRjGMpxoV0A0KnraVSN0C_rx3zo-7e02Po1otV569Qj0p0ME84n1DsvWm_1ZdgqGnXaoGPxlDWTGhAxS_wgi9q-5icHHz4sj-Lwn4MkWY8XkWuNFnJpJYxJNZYrWNWmlglMmeMl8rYvLJSMl0xg2ZB2wqUwYwn04ppyCXPnpDdpm3gGaFKKgDUh0THlmGGyNNEl2BLSJmscstGJBkGQuhQrNztmbEQAyrtTLjBc7tolsJD84oRebuRWfalOm5snQ3jKwYSKppNgZ7kRqnyb1LQhZnfiUR0qYjFH9o5IvlG8oqC__OJ4yvKt3017pLJCm_8etBGgabBrffIBtp1J1wdHwxQsMXTXkm3smWBmWTBn_9np16QO_4ft-dkviS7q_M1vMLgbKXGfvaNya3px_nsyB3nx1_nvwG9ij1_
linkProvider	Elsevier
linkToHtml	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zb9QwELbKVgIkhLhZjtYPvLHR5nAu3lYV1ZZ29wFaqW-Wj7GUKiSrZoNKfws_lnHi7KqCFolXOxM7nvEc8cxnQj6oXOZK4P7WBpjHRKA8EYXCw6ZMRjmE0NVXLJbJ_Ix9OY_Pd8jBUAtj0yqd7u91eqetXcvUreZ0VRTTb7YKOk_CEIU2sMB398gui1Enj8ju7Oh4vtxi77JoUzVtCVztTJ_mdSGEdkiG9lgiuc0-PVqJBlfN9Ndd3O6Pdnbp8Al57BxKOuvn_JTsQPWM3F-4I_Pn5NdMoz1E2wKehOq6_llSiw1-VWiYUEFNcQXa03UDFJcAw-SOUxRdWYquId3kodPaUKEqoD9aW_xRNJ_oV2jact10PbRLTLSZnnA5oTh7XX8vrkFTXbeyxKHRm9UT6hLjS-zocG1fkLPDz6cHc89dyeAplvtrz6KTpUwo4UNgtFHKZ6n2ZSBixvJUahNnRgimMqZRMyiTgdQY9ERKMgWxyKOXZFTVFbwmVAoJgCIRKN8wDBLzMFApmBRCJrLYsDEJBkZw5fDK7bUZJR8S0y64ZZ69SDPlXXZeMiYfNzSrHq3jzqejgb98qENFzcnRmNxJlf6NChq3-Rse8CbkPv9DQMck3lDekPF_jrh3Q_i2n5bbeDLDF-8P0shRO9gjH1FB3TbcQvmgj4JPvOqFdEubJhhMJvmb_5zUPnkwP12c8JOj5fFb8rD75d2VaL4jo_VlC-_RV1vLPbcXfwNwhD6H
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Adapalene-benzoyl+peroxide%2C+a+fixed-dose+combination+for+the+treatment+of+acne+vulgaris%3A+Results+of+a+multicenter%2C+randomized+double-blind%2C+controlled+study&rft.jtitle=Journal+of+the+American+Academy+of+Dermatology&rft.au=Thiboutot%2C+Diane+M.%2C+MD&rft.au=Weiss%2C+Jonathan%2C+MD&rft.au=Bucko%2C+Alicia%2C+DO&rft.au=Eichenfield%2C+Lawrence%2C+MD&rft.date=2007-11-01&rft.issn=0190-9622&rft.volume=57&rft.issue=5&rft.spage=791&rft.epage=799&rft_id=info:doi/10.1016%2Fj.jaad.2007.06.006&rft.externalDBID=ECK1-s2.0-S0190962207010249&rft.externalDocID=1_s2_0_S0190962207010249
thumbnail_m	http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F01909622%2FS0190962207X02378%2Fcov150h.gif